Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Lung Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 95 articles:
HTML format



Single Articles


    November 2020
  1. KANG JH, Lee KH, Kim DW, Kim SW, et al
    A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
    Br J Cancer. 2020 Nov 16. pii: 10.1038/s41416-020-01055.
    PubMed     Abstract available


    October 2020
  2. YANG L, Zhou F, Zhuang Y, Liu Y, et al
    Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
    Br J Cancer. 2020 Oct 30. pii: 10.1038/s41416-020-01135.
    PubMed     Abstract available


  3. HANSEN MS, Licaj I, Braaten T, Lund E, et al
    The fraction of lung cancer attributable to smoking in the Norwegian Women and Cancer (NOWAC) Study.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01131.
    PubMed     Abstract available


  4. SIDDIQUI MA, Gollavilli PN, Ramesh V, Parma B, et al
    Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01095.
    PubMed     Abstract available


  5. CREELAN BC, Yeh TC, Kim SW, Nogami N, et al
    A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
    Br J Cancer. 2020 Oct 5. pii: 10.1038/s41416-020-01099.
    PubMed     Abstract available


    September 2020
  6. KIM TW, Hong DW, Park JW, Hong SH, et al
    CB11, a novel purine-based PPAR ligand, overcomes radio-resistance by regulating ATM signalling and EMT in human non-small-cell lung cancer cells.
    Br J Cancer. 2020 Sep 22. pii: 10.1038/s41416-020-01088.
    PubMed     Abstract available


    July 2020
  7. GOMES F, Wong M, Battisti NML, Kordbacheh T, et al
    Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
    Br J Cancer. 2020 Jul 22. pii: 10.1038/s41416-020-0986.
    PubMed     Abstract available


  8. LUANPITPONG S, Rodboon N, Samart P, Vinayanuwattikun C, et al
    A novel TRPM7/O-GlcNAc axis mediates tumour cell motility and metastasis by stabilising c-Myc and caveolin-1 in lung carcinoma.
    Br J Cancer. 2020 Jul 20. pii: 10.1038/s41416-020-0991.
    PubMed     Abstract available


    June 2020
  9. CICCOLINI J, Benzekry S, Barlesi F
    Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC.
    Br J Cancer. 2020 Jun 16. pii: 10.1038/s41416-020-0918.
    PubMed     Abstract available


  10. ALAM SK, Wang L, Ren Y, Hernandez CE, et al
    ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.
    Br J Cancer. 2020 Jun 5. pii: 10.1038/s41416-020-0923.
    PubMed     Abstract available


    May 2020
  11. ROSSI SM, Ryan BK, Kelly HM
    Evaluation of the activity of a chemo-ablative, thermoresponsive hydrogel in a murine xenograft model of lung cancer.
    Br J Cancer. 2020 May 27. pii: 10.1038/s41416-020-0904.
    PubMed     Abstract available


  12. HSIN IL, Chiu LY, Ou CC, Wu WJ, et al
    CD133 inhibition via autophagic degradation in pemetrexed-resistant lung cancer cells by GMI, a fungal immunomodulatory protein from Ganoderma microsporum.
    Br J Cancer. 2020 May 25. pii: 10.1038/s41416-020-0885.
    PubMed     Abstract available


  13. SURAWEERA A, Duff A, Adams MN, Jekimovs C, et al
    Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer.
    Br J Cancer. 2020 May 22. pii: 10.1038/s41416-020-0899.
    PubMed     Abstract available


  14. WELCH CA, Sweeting MJ, Lambert PC, Rutherford MJ, et al
    Impact on survival of modelling increased surgical resection rates in patients with non-small-cell lung cancer and cardiovascular comorbidities: a VICORI study.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0869.
    PubMed     Abstract available


  15. ZULATO E, Attili I, Pavan A, Nardo G, et al
    Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.
    Br J Cancer. 2020 May 7. pii: 10.1038/s41416-020-0833.
    PubMed     Abstract available


    April 2020
  16. GELSOMINO F, Tiseo M, Barbieri F, Riccardi F, et al
    Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Br J Cancer. 2020 Apr 29. pii: 10.1038/s41416-020-0845.
    PubMed     Abstract available


  17. SAITO R, Miki Y, Abe T, Miyauchi E, et al
    11beta hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0837.
    PubMed     Abstract available


  18. JETTE NR, Radhamani S, Arthur G, Ye R, et al
    Correction: Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Br J Cancer. 2020 Apr 17. pii: 10.1038/s41416-020-0841.
    PubMed     Abstract available


    March 2020
  19. GRIDELLI C, Ciuleanu T, Domine M, Szczesna A, et al
    Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.
    Br J Cancer. 2020 Mar 25. pii: 10.1038/s41416-020-0785.
    PubMed     Abstract available


  20. JEON KH, Shin DW, Han K, Kim D, et al
    Female reproductive factors and the risk of lung cancer in postmenopausal women: a nationwide cohort study.
    Br J Cancer. 2020 Mar 17. pii: 10.1038/s41416-020-0789.
    PubMed     Abstract available


  21. SAITO Y, Takahashi T, Obata Y, Nishida T, et al
    TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naive and imatinib-resistant gastrointestinal stromal tumours.
    Br J Cancer. 2020;122:658-667.
    PubMed     Abstract available


    February 2020
  22. KUEHL PJ, Tellez CS, Grimes MJ, March TH, et al
    5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming.
    Br J Cancer. 2020 Feb 27. pii: 10.1038/s41416-020-0765.
    PubMed     Abstract available


  23. GIATROMANOLAKI A, Harris AL, Banham AH, Contrafouris CA, et al
    Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
    Br J Cancer. 2020 Feb 18. pii: 10.1038/s41416-020-0756.
    PubMed     Abstract available


  24. ACHA-SAGREDO A, Uko B, Pantazi P, Bediaga NG, et al
    Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis.
    Br J Cancer. 2020 Feb 5. pii: 10.1038/s41416-020-0742.
    PubMed     Abstract available


  25. WATTENBERG MM, Asch D, Yu S, O'Dwyer PJ, et al
    Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    Br J Cancer. 2020;122:333-339.
    PubMed     Abstract available


    January 2020
  26. URSO L, Cavallari I, Sharova E, Ciccarese F, et al
    Metabolic rewiring and redox alterations in malignant pleural mesothelioma.
    Br J Cancer. 2020;122:52-61.
    PubMed     Abstract available


    December 2019
  27. HOU P, Shi P, Jiang T, Yin H, et al
    DKC1 enhances angiogenesis by promoting HIF-1alpha transcription and facilitates metastasis in colorectal cancer.
    Br J Cancer. 2019 Dec 20. pii: 10.1038/s41416-019-0695.
    PubMed     Abstract available


  28. MCCUTCHAN G, Smits S, Ironmonger L, Slyne C, et al
    Evaluation of a national lung cancer symptom awareness campaign in Wales.
    Br J Cancer. 2019 Dec 16. pii: 10.1038/s41416-019-0676.
    PubMed     Abstract available


    November 2019
  29. PARK W, Mezquita L, Okabe N, Chae YK, et al
    Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
    Br J Cancer. 2019 Nov 25. pii: 10.1038/s41416-019-0643.
    PubMed     Abstract available


    September 2019
  30. LEONETTI A, Sharma S, Minari R, Perego P, et al
    Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
    Br J Cancer. 2019 Sep 30. pii: 10.1038/s41416-019-0573.
    PubMed     Abstract available


  31. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    PubMed     Abstract available


  32. SCHREIBER LM, Urbiola C, Das K, Spiesschaert B, et al
    The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer.
    Br J Cancer. 2019 Sep 18. pii: 10.1038/s41416-019-0574.
    PubMed     Abstract available


  33. XU Y, Huang Z, Lu H, Yu X, et al
    Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.
    Br J Cancer. 2019 Sep 16. pii: 10.1038/s41416-019-0583.
    PubMed     Abstract available


  34. JETTE NR, Radhamani S, Arthur G, Ye R, et al
    Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Br J Cancer. 2019 Sep 4. pii: 10.1038/s41416-019-0565.
    PubMed     Abstract available


    August 2019
  35. KORPHAISARN K, Morris V, Davis JS, Overman MJ, et al
    Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.
    Br J Cancer. 2019 Aug 13. pii: 10.1038/s41416-019-0548.
    PubMed     Abstract available


  36. YONEDA K, Kuwata T, Kanayama M, Mori M, et al
    Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
    Br J Cancer. 2019 Aug 7. pii: 10.1038/s41416-019-0541.
    PubMed     Abstract available


    July 2019
  37. ELEZ E, Pericay C, Valladares-Ayerbes M, Bando I, et al
    A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
    Br J Cancer. 2019 Jul 31. pii: 10.1038/s41416-019-0537.
    PubMed     Abstract available


  38. LAHEURTE C, Dosset M, Vernerey D, Boullerot L, et al
    Distinct prognostic value of circulating anti-telomerase CD4(+) Th1 immunity and exhausted PD-1(+)/TIM-3(+) T cells in lung cancer.
    Br J Cancer. 2019 Jul 30. pii: 10.1038/s41416-019-0531.
    PubMed     Abstract available


  39. GROEN HJM, van der Heijden EHFM, Klinkenberg TJ, Biesma B, et al
    Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
    Br J Cancer. 2019 Jul 24. pii: 10.1038/s41416-019-0533.
    PubMed     Abstract available


    June 2019
  40. MORGENSZTERN D, Rose M, Waqar SN, Morris J, et al
    RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.
    Br J Cancer. 2019 Jun 24. pii: 10.1038/s41416-019-0504.
    PubMed     Abstract available


    May 2019
  41. SELLERS K, Allen TD, Bousamra M 2nd, Tan J, et al
    Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes.
    Br J Cancer. 2019 May 22. pii: 10.1038/s41416-019-0464.
    PubMed     Abstract available


    April 2019
  42. HEIM L, Kachler K, Siegmund R, Trufa DI, et al
    Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.
    Br J Cancer. 2019 Apr 8. pii: 10.1038/s41416-019-0444.
    PubMed     Abstract available


    March 2019
  43. CREELAN BC, Gray JE, Tanvetyanon T, Chiappori AA, et al
    Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.
    Br J Cancer. 2019 Mar 18. pii: 10.1038/s41416-019-0428.
    PubMed     Abstract available


    February 2019
  44. WU SR, Lin CH, Shih HP, Ko CJ, et al
    HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.
    Br J Cancer. 2019 Feb 15. pii: 10.1038/s41416-019-0400.
    PubMed     Abstract available


  45. KIM SH, Go SI, Song DH, Park SW, et al
    Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer.
    Br J Cancer. 2019 Feb 12. pii: 10.1038/s41416-019-0398.
    PubMed     Abstract available


  46. MAILLE E, Brosseau S, Hanoux V, Creveuil C, et al
    MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
    Br J Cancer. 2019;120:387-397.
    PubMed     Abstract available


    November 2018
  47. TSE LA, Lin X, Li W, Qiu H, et al
    Smoking cessation sharply reduced lung cancer mortality in a historical cohort of 3185 Chinese silicotic workers from 1981 to 2014.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0292.
    PubMed     Abstract available


  48. TIBALDI C, Camerini A, Tiseo M, Mazzoni F, et al
    Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
    Br J Cancer. 2018 Nov 8. pii: 10.1038/s41416-018-0307.
    PubMed     Abstract available


    October 2018
  49. PASSIGLIA F, Cappuzzo F, Alabiso O, Bettini AC, et al
    Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.
    Br J Cancer. 2018 Oct 31. pii: 10.1038/s41416-018-0234.
    PubMed     Abstract available


  50. BECKWITT CH, Clark AM, Ma B, Whaley D, et al
    Statins attenuate outgrowth of breast cancer metastases.
    Br J Cancer. 2018;119:1094-1105.
    PubMed     Abstract available


    September 2018
  51. SASAKI T, Seto T, Yamanaka T, Kunitake N, et al
    A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L.
    Br J Cancer. 2018 Sep 12. pii: 10.1038/s41416-018-0243.
    PubMed     Abstract available


    August 2018
  52. EL-KHOURY V, Beland M, Schritz A, Kim SY, et al
    Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer.
    Br J Cancer. 2018 Aug 6. pii: 10.1038/s41416-018-0200.
    PubMed     Abstract available


    June 2018
  53. ZHENG R, Du M, Zhang B, Xin J, et al
    Body mass index (BMI) trajectories and risk of colorectal cancer in the PLCO cohort.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0121.
    PubMed     Abstract available


    May 2018
  54. ABOU FAYCAL C, Brambilla E, Agorreta J, Lepeltier N, et al
    The sVEGFR1-i13 splice variant regulates a beta1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.
    Br J Cancer. 2018 May 24. pii: 10.1038/s41416-018-0128.
    PubMed     Abstract available


  55. GAO F, Alwhaibi A, Artham S, Verma A, et al
    Endothelial Akt1 loss promotes prostate cancer metastasis via beta-catenin-regulated tight-junction protein turnover.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0110.
    PubMed     Abstract available


    April 2018
  56. BINS S, Basak EA, El Bouazzaoui S, Koolen SLW, et al
    Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0074.
    PubMed     Abstract available


  57. DOHERTY JA, Grieshober L, Houck JR, Barnett MJ, et al
    Nested case-control study of telomere length and lung cancer risk among heavy smokers in the beta-Carotene and Retinol Efficacy Trial.
    Br J Cancer. 2018 Apr 19. pii: 10.1038/s41416-018-0075.
    PubMed     Abstract available


    March 2018
  58. GHOSH KM, Lee LH, Beckingsale TB, Gerrand CH, et al
    Indeterminate nodules in osteosarcoma: what's the follow-up?
    Br J Cancer. 2018;118:634-638.
    PubMed     Abstract available


  59. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
    Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
    Br J Cancer. 2018;118:733-737.
    PubMed     Abstract available


  60. DEL RE M, Marconcini R, Pasquini G, Rofi E, et al
    PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.
    Br J Cancer. 2018 Mar 6. pii: bjc20189. doi: 10.1038/bjc.2018.
    PubMed     Abstract available


    February 2018
  61. HAN B, Li K, Zhao Y, Li B, et al
    Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Br J Cancer. 2018 Feb 13. pii: bjc2017478. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  62. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
    A core matrisome gene signature predicts cancer outcome.
    Br J Cancer. 2018;118:435-440.
    PubMed     Abstract available


    January 2018
  63. SUN JM, Lee KH, Kim BS, Kim HG, et al
    Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
    Br J Cancer. 2018 Jan 30. pii: bjc2017465. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  64. ANTONIO M, Saldana J, Linares J, Ruffinelli JC, et al
    Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.
    Br J Cancer. 2018 Jan 30. pii: bjc2017455. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  65. GADGEEL S, Shaw AT, Barlesi F, Crino L, et al
    Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
    Br J Cancer. 2018;118:38-42.
    PubMed     Abstract available


    November 2017
  66. NANJO S, Hata A, Okuda C, Kaji R, et al
    Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.
    Br J Cancer. 2017 Nov 30. pii: bjc2017394. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    October 2017
  67. THALER J, Sigel C, Beasley MB, Wisnivesky J, et al
    Clinically significant mutations in HIV-infected patients with lung adenocarcinoma.
    Br J Cancer. 2017;117:1392-1395.
    PubMed     Abstract available


  68. O'SULLIVAN D, Dowling P, Joyce H, McAuley E, et al
    A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
    Br J Cancer. 2017;117:1326-1335.
    PubMed     Abstract available


  69. NI Z, Yao C, Zhu X, Gong C, et al
    Ailanthone inhibits non-small cell lung cancer cell growth through repressing DNA replication via downregulating RPA1.
    Br J Cancer. 2017 Oct 12. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  70. VAHL JM, Friedrich J, Mittler S, Trump S, et al
    Interleukin-10-regulated tumour tolerance in non-small cell lung cancer.
    Br J Cancer. 2017 Oct 10. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  71. GABASA M, Ikemori R, Hilberg F, Reguart N, et al
    Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
    Br J Cancer. 2017;117:1128-1138.
    PubMed     Abstract available


    September 2017
  72. GREYSTOKE A, Steele N, Arkenau HT, Blackhall F, et al
    SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
    Br J Cancer. 2017;117:938-946.
    PubMed     Abstract available


  73. KOSHIARIS C, Aveyard P, Oke J, Ryan R, et al
    Smoking cessation and survival in lung, upper aero-digestive tract and bladder cancer: cohort study.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  74. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    PubMed     Abstract available


    August 2017
  75. LI M, Yang J, Zhou W, Ren Y, et al
    Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
    Br J Cancer. 2017 Aug 29. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  76. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Abstract available


  77. ADLER NR, Wolfe R, Kelly JW, Haydon A, et al
    Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  78. CIULEANU TE, Ahmed S, Kim JH, Mezger J, et al
    Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    July 2017
  79. ALEXANDER M, Wolfe R, Ball D, Conron M, et al
    Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer.
    Br J Cancer. 2017 Jul 20. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  80. WINTHER-LARSEN A, Demuth C, Fledelius J, Madsen AT, et al
    Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    June 2017
  81. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Abstract available


  82. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Abstract available


  83. CHERNYAVSKIY P, Edmondson EF, Weil MM, Little MP, et al
    High-energy particle beam and gamma radiation exposure, familial relatedness and cancer in mice.
    Br J Cancer. 2017;117:41-50.
    PubMed     Abstract available


  84. PEDERSEN AB, Horvath-Puho E, Ehrenstein V, Rorth M, et al
    Frozen shoulder and risk of cancer: a population-based cohort study.
    Br J Cancer. 2017;117:144-147.
    PubMed     Abstract available


  85. BARRERA L, Montes-Servin E, Hernandez-Martinez JM, Garcia-Vicente MLA, et al
    CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  86. BAHLEDA R, Grilley-Olson JE, Govindan R, Barlesi F, et al
    Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
    Br J Cancer. 2017;116:1505-1512.
    PubMed     Abstract available


    May 2017
  87. KAZDAL D, Harms A, Endris V, Penzel R, et al
    Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer.
    Br J Cancer. 2017 May 30. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  88. KOINIS F, Agelaki S, Karavassilis V, Kentepozidis N, et al
    Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
    Br J Cancer. 2017 May 16. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    March 2017
  89. MACLEOD AK, Acosta-Jimenez L, Coates PJ, McMahon M, et al
    Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed    


  90. MURUGANANDAN S, Alfonso H, Franklin P, Shilkin K, et al
    Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.
    Br J Cancer. 2017;116:703-708.
    PubMed     Abstract available


  91. MALAPELLE U, Mayo de-Las-Casas C, Rocco D, Garzon M, et al
    Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Br J Cancer. 2017;116:802-810.
    PubMed     Abstract available


    January 2017
  92. BOUCHARD G, Therriault H, Geha S, Bujold R, et al
    Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  93. WU YL, Sequist LV, Hu CP, Feng J, et al
    EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
    Br J Cancer. 2017;116:175-185.
    PubMed     Abstract available


  94. KIM H, Sung JY, Park EK, Kho S, et al
    Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor.
    Br J Cancer. 2017;116:370-381.
    PubMed     Abstract available


    September 2016
  95. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: